On September 11, 2025 RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, reported that the first patient has been dosed in an exploratory Investigational New Drug (IND) study evaluating the diagnostic and targeting efficiency of 203Pb-RMX-VH-PIB in patients with Glioblastoma Multiforme (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC) (Press release, Vect-Horus, SEP 11, 2025, View Source [SID1234656105]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Patients impacted by devastating cancers such as GBM and PDAC often have very poor prognosis and limited effective therapies. 203Pb-RMX-VH-PIB, which is able to cross the blood-brain-barrier, could offer a novel approach for targeting both," said Ebrahim S. Delpassand, M.D., Chief Executive Officer of RadioMedix. "This study will provide the first human insights to guide future clinical development of a theranostic radiopharmaceutical which may ultimately help clinical management for patients. As the licensor of 203Pb-RMX-VH-PIB, we remain committed to supporting its development and advancing innovative diagnostic tools that could improve how we understand and treat such challenging diseases."
The diagnostic imaging product 203Pb-RMX-VH-PIB is an agent that targets the Low-Density Lipoprotein Receptor (LDLR), which is overexpressed in solid tumors such as in GBM and PDAC. In preclinical studies, 203Pb-RMX-VH-PIB demonstrated significant tumor accumulation, a pre-requisite for a successful Targeted Radioligand Therapy (TRT).
The objective of this exploratory clinical study is to evaluate the safety, dosimetry, and distribution of 203Pb-RMX-VH-PIB in patients with GBM, the most aggressive and often fatal brain tumor, and PDAC, one of the most chemo-resistant and lethal cancers. This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers.
"We are pleased to announce the initiation of this clinical trial, which is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix. We are looking forward to generating clinical data with RadioMedix with the aim of expanding treatment options for patients with GBM and PDAC," said Alexandre Tokay, CEO of Vect-Horus.
RadioMedix and Vect-Horus have a co-development and licensing agreement for theranostic agents.